Acute Myeloid Leukemia Pipeline Insights Report 2024 | GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, and others.

DelveInsight's, "Acute Myeloid Leukemia Pipeline Insight 2024" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
• DelveInsight's Acute Myeloid Leukemia pipeline report depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for Acute Myeloid Leukemia treatment.
• The leading companies working in the Acute Myeloid Leukemia market include GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and others.
• Promising Acute Myeloid Leukemia Pipeline Therapies in the various stages of development include OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
• February 2024: Oscotec Inc. announced a study of Phase 1 clinical trials for SKI-G-801. This Phase I study is designed to assess the safety, tolerability, pharmacokinetics and anti-tumor effect of increasing doses of study drug SKI-G-801 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are unresponsive to currently available therapies. Eligible participants will receive cycles of treatment involving IV infusion of SKI-G-801 daily for 14 days followed by 14 days off. Treatment cycles will be repeated until progressive disease or unacceptable toxicity.
• March 2024: AbbVie announced a study of Phase 1 clinical trials for ABBV-787. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in escalating doses until the maximum tolerated dose (MTD) is determined. Approximately 60 adult participants with a diagnosis of AML will be enrolled worldwide.

Request a sample and discover the recent advances in Acute Myeloid Leukemia Treatment Drugs @ Acute Myeloid Leukemia Infection Pipeline Outlook Report- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Acute Myeloid Leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Acute Myeloid Leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acute Myeloid Leukemia clinical trial landscape.

Acute Myeloid Leukemia Overview
Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature "blast cells" in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure.

Find out more about Acute Myeloid Leukemia Treatment Drugs @ Drugs for Acute Myeloid Leukemia Treatment- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Myeloid Leukemia Emerging Drugs Profile

• BST-236: BioSight
Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. The drug is currently in phase II stage of of clinical trial evaluation for the treatment of Acute Myeloid Leukemia (AML).

• Uproleselan: GlycoMimetics
GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. Uproleselan is designed to bind to E-selectin and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling. Uproleselan is designed to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. It is believed that by binding to E-selectin, uproleselan pushes AML cells out of their protective niche, blocks cellular communication signals that promote survival, and sensitizes cancer cells to the toxic effects of chemotherapy. The drug is currently in phase III stage of clinical trial evaluation for the treatment of Acute Myeloid Leukemia (AML).

• MK-0482: Merck Sharp & Dohme LLC
MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase I evaluation ±pembrolizumab (pembro) in advanced solid tumors. MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts.

Acute Myeloid Leukemia Pipeline Therapeutics Assessment
There are approx. 150+ key companies which are developing the Acute Myeloid Leukaemia therapies. The Acute Myeloid Leukaemia companies which have their Acute Myeloid Leukaemia drug candidates in the most advanced stage, i.e preregistration include Gamida Cell.

DelveInsight's Acute Myeloid Leukemia pipeline report covers around 260+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Acute Myeloid Leukaemia Pipeline Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Acute Myeloid Leukemia Pipeline Therapies @ Acute Myeloid Leukemia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acute Myeloid Leukemia Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Acute Myeloid Leukemia Companies- GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and others.
• Acute Myeloid Leukemia Pipeline Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.

Dive deep into rich insights for new drugs for Acute Myeloid Leukemia treatment, Visit @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Acute Myeloid Leukaemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Myeloid Leukaemia- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Omidubicel: Gamida Cell
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase III)
11. Uproleselan: GlycoMimetics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ALT 803: ImmunityBio
15. Early Stage Products (Phase I)
16. JNJ-75276617: Janssen Research & Development, LLC
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. AB001: Agastiya Biotech
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Acute Myeloid Leukaemia Key Companies
23. Acute Myeloid Leukaemia Key Products
24. Acute Myeloid Leukaemia- Unmet Needs
25. Acute Myeloid Leukaemia- Market Drivers and Barriers
26. Acute Myeloid Leukaemia- Future Perspectives and Conclusion
27. Acute Myeloid Leukaemia Analyst Views
28. Acute Myeloid Leukaemia Key Companies
29. Appendix

For further information on the Acute Myeloid Leukemia pipeline therapeutics, reach out @ Acute Myeloid Leukemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://wanneroo-social.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-current-trends-and-future-prospects
https://visbn.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-corneal-healing-challenges
https://globalaffairs.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-in-treatment-and-growing-opportunities
https://snapped.mn.co/posts/navigating-the-persistent-epithelial-defects-market-current-trends-and-future-outlook
https://keywebco.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-unmet-needs-and-driving-innovation
https://machineintelligence.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://healthcaremarketresearch.edublogs.org/2024/03/13/navigating-the-landscape-of-persistent-epithelial-defects-market/
https://lgbtq-youth-chat.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges
https://sarabestexchange73158582.mn.co/posts/unveiling-the-persistent-epithelial-defects-market-a-comprehensive-outlook
https://network-1588972.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://rdd-rapter-gameing.mn.co/posts/persistent-epithelial-defects-market-outlook-addressing-the-unmet-needs-in-ocular-surface-disorders
https://rdd-rapter-gameing.mn.co/posts/persistent-epithelial-defects-market-outlook-addressing-the-unmet-needs-in-ocular-surface-disorders
https://vibe-3-0.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://brand-the-change.mn.co/posts/persistent-epithelial-defects-market-outlook-advancements-and-opportunities
https://goodnow.mn.co/posts/exploring-the-persistent-epithelial-defects-market-a-niche-addressing-corneal-healing-challenges
https://lgbtq-youth-chat.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges-52580993
https://inspiremetoday.mn.co/posts/unraveling-the-persistent-epithelial-defects-market-a-comprehensive-perspective
https://shopsanity.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-innovations-and-challenges
https://plenty-of-heathens.mn.co/posts/navigating-the-persistent-epithelial-defects-market-innovations-and-challenges
https://akademe.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-challenges-and-driving-innovation
https://naijases.mn.co/posts/navigating-the-persistent-epithelial-defects-market-innovations-and-challenges
https://gtribe.mn.co/posts/navigating-the-landscape-of-the-persistent-epithelial-defects-market
https://communenour.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-a-challenging-ophthalmic-condition
https://synkretic.mn.co/posts/navigating-the-landscape-of-the-persistent-epithelial-defects-market
https://lxgonline.mn.co/posts/exploring-the-persistent-epithelial-defects-market-a-comprehensive-analysis
https://regenerative-future.mn.co/posts/exploring-the-persistent-epithelial-defects-market-addressing-an-unmet-need
https://gamebook.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market-challenges-and-opportunities
https://yizhanverse.mn.co/posts/understanding-the-persistent-epithelial-defects-market-a-glimpse-into-emerging-opportunities
https://clinalleve.mn.co/posts/navigating-the-landscape-of-persistent-epithelial-defects-market
https://homes-for-homeless-children.mn.co/posts/52583828
https://weholdspace.mn.co/posts/52584896
https://boringbusiness.mn.co/members/16644151
https://businessboostier.mn.co/posts/52585024
https://amy-anisas-community.mn.co/posts/52585098
https://naitirabotu.mn.co/members/21957308
https://tech4goodwales.mn.co/posts/exploring-the-genital-herpes-market-outlook-trends-treatments-and-future-prospects
https://worldletinews.mn.co/members/20156129
https://local-urban-eats.mn.co/posts/52585609
https://wwwpreparatorianis.mn.co/posts/52585907
https://shaunbook.mn.co/posts/genital-herpes-market-outlook-advancements-and-challenges-ahead
https://playhq.mn.co/posts/52587238
https://linkasia.mn.co/posts/52587360
https://indicate.mn.co/posts/52587525
https://naijases.mn.co/posts/navigating-the-genital-herpes-market-current-trends-and-future-outlook
https://aeros.mn.co/posts/52587883
https://itravel.mn.co/members/20248979
https://churecipe.mn.co/posts/52588055
https://www-network-aus-au.mn.co/posts/genital-herpes-market-outlook-trends-treatments-and-future-prospects
https://mossfon.mn.co/posts/52588854
https://together.mn.co/posts/52589078
https://bipolarjungle.mn.co/posts/52589178
https://create-lifestyle.mn.co/posts/52589248
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/52589494
https://cic-mun.mn.co/posts/52589598
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/52589778

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website- https://www.delveinsight.com/consulting/primary-research-services

This release was published on openPR.